Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
39.90
+2.10 (5.56%)
Jan 21, 2026, 4:08 PM HKT
Biocytogen Pharmaceuticals (Beijing) Employees
Biocytogen Pharmaceuticals (Beijing) had 1,117 employees as of December 31, 2024. The number of employees increased by 51 or 4.78% compared to the previous year.
Employees
1,117
Change (1Y)
51
Growth (1Y)
4.78%
Revenue / Employee
999.22K HKD
Profits / Employee
110.93K HKD
Market Cap
28.00B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 1,117 | 51 | 4.78% |
| Dec 31, 2023 | 1,066 | -282 | -20.92% |
| Dec 31, 2022 | 1,348 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Genscript Biotech | 5,568 |
| Shanghai Henlius Biotech | 3,515 |
| RemeGen | 2,999 |
| Shanghai Junshi Biosciences | 2,578 |
| Zai Lab | 1,869 |
| Keymed Biosciences | 1,258 |
| InnoCare Pharma | 1,089 |
| Ascentage Pharma Group International | 567 |
Biocytogen Pharmaceuticals (Beijing) News
- 4 months ago - Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions - Financial Post
- 6 months ago - Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website - Business Upturn
- 6 months ago - Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development - Financial Post
- 7 months ago - Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing - Financial Post
- 8 months ago - Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform - Business Upturn
- 8 months ago - Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009) - Financial Post
- 1 year ago - Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors - Financial Post